Survodutide
GLP-1/Glucagon Dual Receptor Agonist
Amino Acids
N/A
Molecular Weight
~4,200 Da
Half-life
~5.5 days
Research Score
4.4
Studies
32
Storage
N/A
What is Survodutide?
Survodutide is a dual GLP-1 and glucagon receptor agonist being developed by Boehringer Ingelheim. It has shown remarkable results for both weight loss and non-alcoholic steatohepatitis (NASH/MASH), significantly reducing liver fat content while achieving substantial weight loss.
Key Benefits & Mechanisms
Significant weight loss (up to 19%)
Dramatic liver fat reduction
NASH/MASH improvement
Improved metabolic biomarkers
Dual pathway activation
Hepatoprotective effects
Cardiovascular risk reduction
Research Summary
Survodutide Phase II trials showed 18.7% weight loss and up to 87% reduction in liver fat in NASH patients. Particularly promising for the large unmet need in NASH/MASH treatment. Multiple Phase III trials ongoing for both obesity and liver disease.
Related Peptides
Semaglutide
GLP-1 Receptor Agonist
Semaglutide is a GLP-1 receptor agonist with proven efficacy for weight management and glycemic control. FDA-approved as Ozempic (diabetes) and Wegovy (weight management), it mimics the incretin hormone GLP-1 to regulate appetite and blood sugar.
MetabolicTirzepatide
GIP/GLP-1 Dual Receptor Agonist
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight management). It offers superior weight loss compared to GLP-1-only agonists by targeting two incretin pathways simultaneously.
MetabolicAOD-9604
Anti-Obesity Drug (Modified GH Fragment)
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 177-191) specifically designed for fat metabolism. It stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or tissue growth, making it a targeted fat-loss peptide without typical GH side effects.
MetabolicTesamorelin
Synthetic Growth Hormone Releasing Hormone
Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved as Egrifta for HIV-associated lipodystrophy, it reduces visceral adipose tissue while maintaining peripheral fat and improving body composition. Produces physiological GH release.
Metabolic